7 Most Profitable Biotech Stocks To Buy Right Now
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
United Therapeutics Corp (UTHR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 2,760,300 | $973,944,252 | -4% | 13.77% |
| 2. | Renaissance Technologies Jim Simons | 2,089,392 | $737,221,073 | -4% | 1.09% |
| 3. | AQR Capital Management Cliff Asness | 975,444 | $344,175,661 | +1% | 0.44% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 542,445 | $191,396,294 | -16% | 0.15% |
| 5. | Palo Alto Investors William Leland Edwards | 155,714 | $54,942,128 | -16% | 8.51% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.83 | 4 | Director | 1,684 | 2019-06-10 | Filing | |
| $114.06 | 6 | Director | 1,686 | 2018-04-20 | Filing | |
| $126.20 | 5 | Director | 1,685 | 2017-11-20 | Filing | |
| $128.35 | 3 | Director | 1,686 | 2017-07-28 | Filing | |
| $130.24 | 3 | Director | 1,683 | 2017-07-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $285.16 | 3,000 | 1,750 | 2025-04-14 | Filing | ||
| $284.55 | 4,000 | 1,750 | 2025-04-07 | Filing | ||
| $308.08 | 1,501 | 36,781 | 2025-04-03 | Filing | ||
| $307.12 | 3,787 | 38,282 | 2025-04-03 | Filing | ||
| $306.08 | 2,218 | 42,069 | 2025-04-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 124,900 | $38,502,863 | 0.04% | |
| 2. | 107,276 | $33,069,973 | 0.64% | |
| 3. | 65,405 | $20,162,399 | 0.03% | |
| 4. | 63,696 | $19,635,566 | 1.36% | |
| 5. | 58,574 | $18,056,607 | 4.46% |
News See All
10 Best Healthcare Stocks For Long-Term Investment
In the US, healthcare expenditures and costs have been increasing. According to the Centers for Medicare & Medicaid Services, US healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023.
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Call Transcript February 26, 2025United Therapeutics Corporation beats earnings expectations.
Renaissance Technologies Portfolio: Top 10 Stock Picks
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs.
10 Cheap Biotech Stocks to Invest in Now
Biotechnology stocks are among the most volatile in the market due to their high risk.
12 Cheap Healthcare Stocks to Buy Heading into 2025
Investing in healthcare equities is typically seen as protective during recessionary times.
Here are Updates on United Therapeutics Corp. (UTHR)
Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the same can be downloaded here.
10 Best Performing Biotech Stocks in 2024
The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and government assistance.
United Therapeutics Corporation (NASDAQ:UTHR) Q3 2024 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q3 2024 Earnings Call Transcript October 30, 2024United Therapeutics Corporation misses on earnings expectations.
Renaissance Technologies Portfolio: 10 Best Stocks To Buy
Renaissance Technologies is an American hedge fund that specializes in systematic trading and employs statistical and mathematical tools to drive its investment programs.
Billionaire Hedge Funds
